CYPB - Cypress BioScience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dwight martin who wrote (396)	9/16/1998 5:39:00 PM
From: growthvalue	Read Replies (3) of 586

"This 10% figure does not encompass the new drugs (Enbrel? Arava?), does it?" There's no way it could. Pricing wise, I'd imagine it would fall between Enbrel (more expensive) and Arava (less expensive). I have seen no mention of side effects observed in trials - are there any serious ones? Finally, on putting the machines in a doctor's office - I'd imagine it would make a lot more sense for the rheumatologist to refer the patient to a clinic that already has the machines. GV

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next